Reviva Pharmaceuticals Holdings (RVPH) Earnings Call Presentation

Reviva Pharmaceuticals Reviva | Corporate Presentation 3 Phase 3 RECOVER Open-Label Extension (OLE) Trial of Brilaroxazine in Schizophrenia June 2, 2025 at 8:00am EDT Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's expectations regarding the anticipate ...